BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Santos-Morales O, Díaz-Machado A, Jiménez-Rodríguez D, Pomares-Iturralde Y, Festary-Casanovas T, González-Delgado CA, Pérez-Rodríguez S, Alfonso-Muñoz E, Viada-González C, Piedra-Sierra P, García-García I, Amaro-González D, García-Rodríguez JC, Sosa-Testé I, Lagarto-Parra A, Barrero-Viera L, David-Baldo M, Tamayo-Rodríguez M, Rivero-Vázquez I, González-Gamiz G, Martín-Trujillo A, Rodríguez-Fernández Y, Ledo-de la Luz AA, Álvarez-Delgado M, Howland-Álvarez I, Cruz-Gómez Y; NeuroEPO Study Group. Nasal administration of the neuroprotective candidate NeuroEPO to healthy volunteers: a randomized, parallel, open-label safety study. BMC Neurol 2017;17:129. [PMID: 28676085 DOI: 10.1186/s12883-017-0908-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
Number Citing Articles
1 Boesch S, Indelicato E. Erythropoietin and Friedreich Ataxia: Time for a Reappraisal? Front Neurosci 2019;13:386. [PMID: 31105516 DOI: 10.3389/fnins.2019.00386] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
2 Ameratunga R, Woon ST, Steele R, Snell R, Medlicott N, Mears E, Leung E, Lehnert K, Jordan A, Das S, Abbott W, Longhurst H, Quiñones-Mateu ME. Perspective: the nose and the stomach play a critical role in the NZACE2-Pātari* (modified ACE2) drug treatment project of SARS-CoV-2 infection. Expert Rev Clin Immunol 2021;17:553-60. [PMID: 33792473 DOI: 10.1080/1744666X.2021.1912596] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Vissers MFJM, Heuberger JAAC, Groeneveld GJ. Targeting for Success: Demonstrating Proof-of-Concept with Mechanistic Early Phase Clinical Pharmacology Studies for Disease-Modification in Neurodegenerative Disorders. Int J Mol Sci 2021;22:1615. [PMID: 33562713 DOI: 10.3390/ijms22041615] [Reference Citation Analysis]
4 Meneses G, Cárdenas G, Espinosa A, Rassy D, Pérez-osorio IN, Bárcena B, Fleury A, Besedovsky H, Fragoso G, Sciutto E. Sepsis: developing new alternatives to reduce neuroinflammation and attenuate brain injury: Alternatives to modulate neuroinflammation. Ann N Y Acad Sci 2019;1437:43-56. [DOI: 10.1111/nyas.13985] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 6.5] [Reference Citation Analysis]
5 Ma Y, Zhou Z, Yang G, Ding J, Wang X. The Effect of Erythropoietin and Its Derivatives on Ischemic Stroke Therapy: A Comprehensive Review. Front Pharmacol 2022;13:743926. [DOI: 10.3389/fphar.2022.743926] [Reference Citation Analysis]
6 Vittori DC, Chamorro ME, Hernández YV, Maltaneri RE, Nesse AB. Erythropoietin and derivatives: Potential beneficial effects on the brain. J Neurochem 2021. [PMID: 34278579 DOI: 10.1111/jnc.15475] [Reference Citation Analysis]
7 Wang Z, Xiong G, Tsang WC, Schätzlein AG, Uchegbu IF. Nose-to-Brain Delivery. J Pharmacol Exp Ther 2019;370:593-601. [PMID: 31126978 DOI: 10.1124/jpet.119.258152] [Cited by in Crossref: 43] [Cited by in F6Publishing: 38] [Article Influence: 14.3] [Reference Citation Analysis]
8 Gratpain V, Mwema A, Labrak Y, Muccioli GG, van Pesch V, des Rieux A. Extracellular vesicles for the treatment of central nervous system diseases. Adv Drug Deliv Rev 2021;174:535-52. [PMID: 33991589 DOI: 10.1016/j.addr.2021.05.006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
9 Goel H, Kalra V, Verma SK, Dubey SK, Tiwary AK. Convolutions in the rendition of nose to brain therapeutics from bench to bedside: Feats & fallacies. J Control Release 2021;341:782-811. [PMID: 34906605 DOI: 10.1016/j.jconrel.2021.12.009] [Reference Citation Analysis]
10 Robinson-Agramonte MLA, Pedre LL, Serrano-Barrera OR. Neuroimmunology Research. A Report from the Cuban Network of Neuroimmunology. Behav Sci (Basel) 2018;8:E47. [PMID: 29738432 DOI: 10.3390/bs8050047] [Reference Citation Analysis]
11 Hwang CH. Targeted Delivery of Erythropoietin Hybridized with Magnetic Nanocarriers for the Treatment of Central Nervous System Injury: A Literature Review. Int J Nanomedicine 2020;15:9683-701. [PMID: 33311979 DOI: 10.2147/IJN.S287456] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
12 Kunze R, Marti HH. Angioneurins - Key regulators of blood-brain barrier integrity during hypoxic and ischemic brain injury. Prog Neurobiol 2019;178:101611. [PMID: 30970273 DOI: 10.1016/j.pneurobio.2019.03.004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
13 García-artalejo JA, Mancera-arteu M, Sanz-nebot V, Rodríguez T, Giménez E. CHARACTERIZING A NOVEL HYPOSIALYLATED ERYTHROPOIETIN BY INTACT GLYCOPROTEIN AND GLYCAN ANALYSIS. Journal of Pharmaceutical and Biomedical Analysis 2022. [DOI: 10.1016/j.jpba.2022.114686] [Reference Citation Analysis]
14 Rodriguez-Labrada R, Ortega-Sanchez R, Hernández Casaña P, Santos Morales O, Padrón-Estupiñan MDC, Batista-Nuñez M, Jiménez Rodríguez D, Canales-Ochoa N, Peña Acosta A, Medrano Montero J, Labrada Aguilera PE, Estupiñán Rodriguez A, Vazquez-Mojena Y, Almaguer Gotay D, Aymed-García J, García-García I, Torres Vega R, Viada González C, Valenzuela Silva CM, Silva Ricardo Y, Columbié Ximelis J, Tribin Rivero K, Valle Cabrera R, García-Rodriguez JC, Crombet Ramos T, Amaro-González D, Rodriguez-Obaya T, Velázquez-Pérez L. Erythropoietin in Spinocerebellar Ataxia Type 2: Feasibility and Proof-of-Principle Issues from a Randomized Controlled Study. Mov Disord 2022. [PMID: 35607776 DOI: 10.1002/mds.29045] [Reference Citation Analysis]